美国护理点诊断市场评估：按产品、按处方、按最终用户、按地区、机会、预测（2017-2031 年）

美国即时诊断市场规模预计将从 2023 年的 174.7 亿美元增至 2031 年的 258.1 亿美元，预计 2024-2031 年的复合年增长率为 5.00%。市场成长的推动因素包括该国传染病患者数量的增加、早期检测意识的提高、对小型便携式诊断设备的偏好增加、私人和政府资金的增加、研发投资的增加，这是技术进步的支持。

在 COVID-19 大流行之后，随着对可靠、快速和方便的检测的需求变得更加明显，即时诊断 (PCOD) 市场出现了显着增长。大流行期间卫生系统面临的课题清楚地表明，所有人，特别是生活在偏远地区的人们，都需要获得足够的优质照护。医疗保健优先事项正在发生变化，增加了对患者持续访问和可靠诊断工具的需求。人工智慧、生物感测器、奈米技术和智慧型手机平台等技术创新正在提高护理点诊断的准确性和速度。将这些先进技术与电子健康记录 (EHR) 结合併增加 CLIA 豁免测试也是患者护理的一个重要转变。美国研发资金的增加也加速了市场的可负担性和可近性，改善了全国的健康状况。

此外，该公司正在投资创新技术并简化审批流程，以增加检测的机会并最终改善患者的治疗结果。例如，2024 年 6 月，Co-Diagnostics, Inc. 为 Co-Dx PCR Pro 设备申请了上市前核准 (PMA)。该设备将金标准 PCR 测试从传统上仅限于大型、复杂的实验室中转移出来，使发展中国家更容易进行传染病诊断。该公司开发了一种小型化、智慧型手机控制的设备，并正在利用其专利的 Co-Dx Co-Primers 技术寻求 FDA 510(k) 许可。

本报告研究和分析了美国即时诊断市场，提供市场规模和预测、市场动态和主要参与者趋势。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第4章美国即时诊断市场展望（2017-2031）

• 市场规模分析与预测
  • 数量
• 市占率分析与预测
  • 按产品
  • 按处方
  • 按最终用户
  • 按地区
  • 市场占有率分析：按公司划分（金额）（前 5 名公司及其他 - 2023 年）
• 市场地图分析（2023）
  • 按产品
  • 按处方
  • 按最终用户
  • 按地区

第5章 供需分析

第6章 进出口分析

第7章 价值链分析

第8章 波特五力分析

第9章PESTLE分析

第10章价格分析

第11章 市场动态

• 市场驱动力
• 市场课题

第12章 市场趋势和发展

第13章 监理框架与创新

• 监管审批

第14章 专利情况

第15章案例研究

第16章 竞争格局

• 前5名市场领导者的竞争矩阵
• 前5名企业SWOT分析
• 前10名主要企业状况
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc.
  • Abbott Laboratories
  • Cepheid Inc.
  • Co-Diagnostics, Inc.
  • Visby Medical, Inc.
  • SEKISUI Diagnostics LLC
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Nova Biomedical Corporation

第17章 战略建议

第18章 关于我们公司、免责声明

United States point-of-care diagnostics market is projected to witness a CAGR of 5.00% during the forecast period 2024-2031, growing from USD 17.47 billion in 2023 to USD 25.81 billion in 2031. The market growth is supported by influenced by the rising number of infectious cases in the country, increasing awareness for early detection, increasing preference for compact and portable diagnostic devices, growing private and government funding, increased research and development investments, and technological advancements.

The point-of-care diagnostics (PCOD) market is witnessing significant growth post-COVID-19 pandemic as the need for reliable, rapid, and accessible testing becomes more apparent. Challenges in the healthcare system during the pandemic have revealed the need for adequate quality care, particularly for all those in more remote areas. Healthcare priorities are changing, and there is a growing need for continuous patient access and trusted diagnostic tools. Innovations such as artificial intelligence, biosensors, nanotechnology, and smartphone platforms improve the capabilities of the accuracy and speed of diagnostics at the point-of-care. Integrating these advanced technologies with electronic health records (EHR) and the growth of CLIA-waived tests are also a significant transition to patient care. Increased funding for research and development in the United States also accelerates the market toward affordability and accessibility, improving health outcomes across the country.

Moreover, companies are investing in innovations and streamlining the approval process to boost testing access, ultimately driving improved patient outcomes. For instance, in June 2024, Co-Diagnostics, Inc. submitted its pre-market approval (PMA)application for the Co-Dx PCR Pro device that will eventually migrate the gold-standard PCR test from the large, complex laboratories to which it has been confined to this point and make infectious disease diagnostics more accessible in the developing world. The company created miniaturized, smartphone-controllable devices and is pursuing FDA 510(k) clearance through patented Co-Dx Co-Primers technology.

Technological Advancements Drive Market Growth

Technological advancements in the United States Point-of-Care Diagnostics (POCD) market improve the accuracy and efficiency of tests conducted in the Point-of-Care Diagnostics environment. Mobile equipment, such as handheld analyzers, portable ultrasound machines, and mobile labs, enable healthcare providers to make quicker assessments outside traditional settings and, therefore, has improved access in other underserved areas. For example, in June 2024, Cepheid Inc. received FDA marketing authorization for its Xpert HCV test, and GeneXpert Xpress System, the first in the family of hepatitis C virus testing solutions that will be used in the approved point-of-care setting for diagnosing individuals at risk for hepatitis C. Lastly, artificial intelligence is also reshaping diagnostics as it assists in interpreting outcome results, detecting trends, and forecasting outcomes.

For instance, in October 2024, HueDx, Inc. (HueDx) published a study demonstrating the utility of its smartphone-based, paper-driven quantitative diagnostic platform, HueTools and HueLab. Such innovation finally overcomes earlier limitations of demonstrating reliable point-of-care clinical chemistry colorimetric results without additional hardware. These innovations make the diagnosis process easier and provide a healthy boost for the whole market due to portable solutions for testing, improved patient care, and accessibility throughout the country.

Rising Prevalence of Infectious Diseases

Several factors have led to an upsurge of infectious diseases in the United States, including increased international traveling, urbanization, antibiotic resistance, and climatic changes that affect the disease vectors. Other factors include the aged population and increased vulnerability to disease. According to the U.S. Centers for Disease Control and Prevention, new HIV infections occurred in the United States in the year 2022. The country aims to reduce this figure from 32,800 in 2022 to 9,300 in the year 2025 and even lower to 3000 in 2030. As these infections increase, the need for Point-of-Care Diagnostics (POCD) also rises, mainly because of the urgent demand for quick access to testing and rapid therapy. POCD facilitates early detection and treatment, which are fundamental to controlling epidemics and better patient care. Therefore, such increasing demand propels the point-of-care diagnostic market in the United States.

Given the surging demand, companies and governments are working. For example, in April 2024, Cepheid Inc., a subsidiary of Danaher Corporation, received WHO prequalification for its Xpert HIV-1 Qual XC-an in vitro test that is available for the detection of HIV-1 in blood samples.

Increasing Funding or Investments Promote Market Growth

Increasing funding from the government and the private sector is a major driver in point-of-care diagnostics market growth in the United States. Such funding improves more advanced and reliable diagnostic technologies, thus furthering the capabilities and accessibility of tests. Funding for research and innovation results in the development of portable devices and efficient testing schemes that can be fitted into many healthcare settings. Therefore, the market is rapidly advancing in response to the growing requirements for more timely and accurate diagnostics. For instance, in April 2024, Binx Health Inc. raised USD 65 million in Series F funding toward further company growth. They plan to expand their point-of-care diagnostics growth by focusing on speeding up the time between diagnosis and treatment of sexually transmitted diseases. Binx io is the FDA-cleared platform by which Binx aims to accelerate the speed of diagnosis and treatment for sexually transmitted infections. Results from tests for chlamydia and gonorrhea return within 30 minutes.

Product Segment Accounts for Significant Market Share

The glucose monitoring segment is the most dominant in the Point-of-Care Diagnostics market, as diabetes prevails highly in the United States and constantly forces the demand for better self-monitoring products that are easy to use. The advancement of technologies, such as continuous glucose monitors and smart devices, which can be connected to a mobile application, drive this segment that gives the user real-time data and insights. Further, health initiatives that are coming up in the form of diabetes management and education are pushing for the adoption of these tools. Glucose monitoring is thus gaining dominance through the enormous investment it brings into market growth while improving patient engagement and outcomes, thus becoming an important area in the healthcare sector.

For instance, in August 2024, DexCom, Inc. introduced the Stelo, the first over-the-counter glucose biosensor in the U.S. This small device is used to be worn on the upper arm, uses advanced sensing technology to provide personalized glucose insights to the 125 million Americans who suffer from Type 2 diabetes and prediabetes.

Future Market Scenario (2024-2031F)

The integration of artificial intelligence and machine learning in diagnostic devices will ensure accurate and more efficient test results. A significant expansion of telehealth services would also occur since consultation through remote platforms often requires rapid turnaround solutions to ensure the timely treatment of patients. As the trends evolve, the scope for a point-of-care diagnostics market will flourish with a holistic transformation in healthcare delivery.

Increasing investments along with enhanced awareness are promising signs of further expansion of the point-of-care diagnostics market. For example, in April 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) funded USD 1 million to Scout Health Inc. (previously known as Uh-Oh Labs, Inc.), a diagnostics and health-tech company, to develop the STI Scout test, which can differentiate Neisseria gonorrhoeae from Chlamydia trachomatis in just 30 minutes, quickly and affordably.

Key Players Landscape and Outlook

The major players for point-of-care diagnostics in the United States focus on strategic alliances, product innovation, and expanding their channel network distribution to enhance market positions. Investments in research and development will be utilized to introduce new diagnostic solutions at the cutting edge of healthcare demand.

In September 2024, Cepheid Inc. (Cepheid) collaborated with the Fleming Initiative and committed itself to combat global antimicrobial resistance, a global collaboration being spearheaded by Imperial College Healthcare NHS Trust and Imperial College London. Cepheid has become the first diagnostics company to join this endeavor as it applauds its new partnership at an event in New York to coincide with the UN General Assembly High-Level Meeting on AMR.

In June 2022, Visby Medical, Inc. added USD 35 million to its already existing funding round, Series E financing round, taking the total amount to over USD 135 million. Supported by Lightrock LLP, the new capital will help Visby Medical grow its production capacity, increase product lines with advanced respiratory health tests and antimicrobial resistance panels, and provide at-home PCR diagnostics.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. United States Point-of-Care Diagnostics Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. Glucose Monitoring
      • 4.2.1.1.1. Strips
      • 4.2.1.1.2. Meters
      • 4.2.1.1.3. Lancets
    • 4.2.1.2. Cardiometabolic Testing Products
      • 4.2.1.2.1. Cardiac Marker Testing Products
        • 4.2.1.2.1.1. High Sensitive Troponin-I (hsTnl)
        • 4.2.1.2.1.2. Brain natriuretic peptide (BNP)
        • 4.2.1.2.1.3. D-dimer
        • 4.2.1.2.1.4. Creatine Kinase-MB (CK-MB)
        • 4.2.1.2.1.5. Myoglobin
        • 4.2.1.2.1.6. Others
      • 4.2.1.2.2. Blood Gas/Electrolytes Testing Products
      • 4.2.1.2.3. HbA1C Testing Products
    • 4.2.1.3. Infectious Disease Testing Products
      • 4.2.1.3.1. Sexually Transmitted Disease (STD) Testing Products
      • 4.2.1.3.2. Healthcare-associated Infection (HAI) Testing Products
      • 4.2.1.3.3. Respiratory Infection Testing Products
      • 4.2.1.3.4. Tropical Disease Testing Products
      • 4.2.1.3.5. Others
    • 4.2.1.4. Coagulation Testing Products
      • 4.2.1.4.1. PT/INR Testing Products
      • 4.2.1.4.2. Activated Clotting Time/Activated Partial Thromboplastin Clotting Time (ACT/APTT) Testing Products
    • 4.2.1.5. Pregnancy and Fertility Testing Products
      • 4.2.1.5.1. Pregnancy Testing Products
      • 4.2.1.5.2. Fertility Testing Products
    • 4.2.1.6. Tumor/Cancer Marker Testing Products
    • 4.2.1.7. Cholesterol Testing Products
    • 4.2.1.8. Hematology Testing Products
    • 4.2.1.9. Drug-of-Abuse (DoA) Testing Products
    • 4.2.1.10. Fecal Occult Testing Products
    • 4.2.1.11. Urinalysis Testing Products
    • 4.2.1.12. Others
  • 4.2.2. By Prescription
    • 4.2.2.1. OTC Testing
    • 4.2.2.2. Prescription-based Testing
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Diagnostic Centers
    • 4.2.3.3. Research Laboratories
    • 4.2.3.4. Homecare Settings
    • 4.2.3.5. Others
  • 4.2.4. By Region
    • 4.2.4.1. Northeast
    • 4.2.4.2. Midwest
    • 4.2.4.3. West
    • 4.2.4.4. South
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Product
  • 4.3.2. By Prescription
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. GE HealthCare Technologies Inc.
  • 16.3.3. Abbott Laboratories
  • 16.3.4. Cepheid Inc.
  • 16.3.5. Co-Diagnostics, Inc.
  • 16.3.6. Visby Medical, Inc.
  • 16.3.7. SEKISUI Diagnostics LLC
  • 16.3.8. Becton, Dickinson and Company
  • 16.3.9. BioMerieux SA
  • 16.3.10. Nova Biomedical Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Point-of-Care Diagnostics Market, By Value, In USD Billion, 2017-2031F
• Figure 2. United States Point-of-Care Diagnostics Market Share (%), By Product, 2017-2031F
• Figure 3. United States Point-of-Care Diagnostics Market Share (%), By Prescription, 2017-2031F
• Figure 4. United States Point-of-Care Diagnostics Market Share (%), By End-user, 2017-2031F
• Figure 5. United States Point-of-Care Diagnostics Market Share (%), By Region, 2017-2031F
• Figure 6. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 7. By Prescription Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 8. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 9. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023